Annual Cash & Cash Equivalents
$14.58 M
+$1.12 M+8.35%
December 31, 2023
Summary
- As of February 8, 2025, EPRX annual cash & cash equivalents is $14.58 million, with the most recent change of +$1.12 million (+8.35%) on December 31, 2023.
- During the last 3 years, EPRX annual cash & cash equivalents has risen by +$14.46 million (+12287.43%).
- EPRX annual cash & cash equivalents is now -11.02% below its all-time high of $16.39 million, reached on December 1, 2021.
Performance
EPRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$8.66 M
-$14.65 M-62.85%
September 1, 2024
Summary
- As of February 8, 2025, EPRX quarterly cash and cash equivalents is $8.66 million, with the most recent change of -$14.65 million (-62.85%) on September 1, 2024.
- Over the past year, EPRX quarterly cash and cash equivalents has dropped by -$14.65 million (-62.85%).
- EPRX quarterly cash and cash equivalents is now -75.88% below its all-time high of $35.91 million, reached on March 31, 2024.
Performance
EPRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
EPRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.3% | -62.9% |
| 3 y3 years | +10000.0% | -47.1% |
| 5 y5 years | +2311.5% | - |
EPRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -11.0% | +8.3% | -75.9% | +0.4% |
| 5 y | 5-year | -11.0% | >+9999.0% | -75.9% | +7259.2% |
| alltime | all time | -11.0% | >+9999.0% | -75.9% | +7259.2% |
Eupraxia Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $8.66 M(-62.9%) |
| Jun 2024 | - | $23.32 M(-35.1%) |
| Mar 2024 | - | $35.91 M(+85.6%) |
| Dec 2023 | $14.58 M(+8.3%) | $19.34 M(-20.8%) |
| Sep 2023 | - | $24.43 M(+69.6%) |
| Jun 2023 | - | $14.41 M(-21.1%) |
| Dec 2022 | $13.46 M | - |
| Dec 2022 | - | $18.26 M(+111.6%) |
| Sep 2022 | - | $8.63 M(-36.1%) |
| Jun 2022 | - | $13.50 M(-0.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $13.52 M(-17.5%) |
| Dec 2021 | $16.39 M(>+9900.0%) | $16.39 M(-37.9%) |
| Sep 2021 | - | $26.39 M(-9.3%) |
| Jun 2021 | - | $29.10 M(+18.0%) |
| Mar 2021 | - | $24.65 M(>+9900.0%) |
| Dec 2020 | $117.70 K(-86.7%) | $117.70 K(-63.3%) |
| Sep 2020 | - | $320.60 K(-63.8%) |
| Dec 2019 | $885.00 K(+46.4%) | $885.00 K |
| Dec 2018 | $604.60 K(-80.9%) | - |
| Dec 2017 | $3.17 M | - |
FAQ
- What is Eupraxia Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Eupraxia Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Eupraxia Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of EPRX is $14.58 M
What is the all time high annual cash & cash equivalents for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high annual cash & cash equivalents is $16.39 M
What is Eupraxia Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, EPRX annual cash & cash equivalents has changed by +$1.12 M (+8.35%)
What is Eupraxia Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of EPRX is $8.66 M
What is the all time high quarterly cash and cash equivalents for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high quarterly cash and cash equivalents is $35.91 M
What is Eupraxia Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, EPRX quarterly cash and cash equivalents has changed by -$14.65 M (-62.85%)